Feb 04, 2021 / 08:30AM GMT
Operator
Hello, and welcome to the BioArctic Q4 reports 2020. (Operator Instructions) Just to remind you this conference call is being recorded. Today, I'm pleased to present CEO, Gunilla Osswald; and CFO, Jan Mattsson. Please go ahead. (foreign language)
Gunilla Osswald - BioArctic AB(publ)-CEO
Thank you, and welcome to BioArctic's full year report for 2020. I'm Gunilla Osswald, and I'm the CEO of BioArctic. I will share this presentation today with our CFO, Jan Mattsson.
2020 was a very good year for BioArctic in spite the tough situation around us with the COVID-19 pandemic. Our great project portfolio progressed well, thanks to our great personnel and our great partners.
Eisai has, during 2020, broadened the scope for lecanemab, BAN2401 and has now 2 Phase III programs ongoing. Yesterday, we also announced that the number of patients in Clarity AD, the pivotal Phase III study, has been increased to ensure a robust data set.
We have also reported that continues to strengthen the support phenomena during
Full Year 2020 BioArctic AB Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
